SCSarika Chaudhary

Sarika Chaudhary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarika Chaudhary has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Kanupriya Jha

    Department of Biotechnology, School of Engineering and Applied Sciences, Bennett University, Greater Noida, India

    7 shared publications
  • Adrian R. Black

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA

    3 shared publications
  • Ajay Jain

    Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, USA

    3 shared publications
  • Amarnath Natarajan

    Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, USA

    3 shared publications
  • Amit Kumar

    Department of Biotechnology, School of Engineering and Applied Sciences, Bennett University, Greater Noida, Uttar Pradesh, India

    3 shared publications
  • Aneesha Dasgupta

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA

    3 shared publications

Latest Publications

  • Open Access

    Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis

    by Divya Murthy, Kuldeep S. Attri, Surendra K. Shukla, Ravi Thakur, Nina V. Chaika, Chunbo He, Dezhen Wang, Kanupriya Jha, Aneesha Dasgupta, Ryan J. King, et al.

  • Roadmap to Cytotoxicity: Exploring Assays and Mechanisms

    by Kirtivardhan Singh Shekhawat, Piyush Bhatia, Kartik Bhatnagar, Swati Shandilay, Sarika Chaudhary

    Cytotoxicity assays are essential in the field of research as they enable the examination of cellular responses to stimuli and shed light on complex mechanisms involved in multiple diseases and drug development. This review covers a range of cytotoxicity assays, including trypan blue and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assays, to more advanced techniques like caspase activity assays, Lactate dehydrogenase release assays, comet assays, and micronucleus assays for DNA damage assessment. Apart from these, other relevant assays like Alamar Blue, Bromodeoxyuridine incorporation, and clonogenic cell survival are also discussed. In this study, significance of these assays in drug development, toxicology studies, and biomedical research is discussed in detail, highlighting their role in ensuring safety and unraveling disease mechanisms. Furthermore, we explore emerging technologies such as chip-based assays, organ-on-a-chip systems, and high-throughput screening, which enhance precision and efficiency in research. Despite these advancements, challenges remain that necessitate standardization efforts and the development of more refined models. In conclusion, this review reflects on the evolving landscape of cytotoxicity assays, finding a balance between traditional methodologies and cutting-edge technologies.


  • Targeting mineral metabolism in cancer: Insights into signaling pathways and therapeutic strategies

    by Kartik Bhatnagar, Sharon Raju, Ninad Patki, Rajender K. Motiani, Sarika Chaudhary


  • Open Access

    Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy

    by Kartik Bhatnagar, Kanupriya Jha, Nishu Dalal, Ninad Patki, Garima Gupta, Amit Kumar, Anil Kumar, Sarika Chaudhary

    The human microbiome is the complex ecosystem consisting of trillions of microorganisms that play a key role in developing the immune system and nutrient metabolism. Alterations in the gut microbiome have been linked to cancer initiation, progression, metastasis, and response to treatment. Accumulating evidence suggests that levels of vitamins and minerals influence the gut environment and may have implications for cancer risk and progression. Bifidobacterium has been reported to reduce the colorectal cancer risk by binding to free iron. Additionally, zinc ions have been shown to activate the immune cells and enhance the effectiveness of immunotherapy. Higher selenium levels have been associated with a reduced risk of several cancers, including colorectal cancer. In contrast, enhanced copper uptake has been implicated in promoting cancer progression, including colon cancer. The interaction between cancer and gut bacteria, as well as dysbiosis impact has been studied in animal models. The interplay between prebiotics, probiotics, synbiotics, postbiotics and gut bacteria in cancer offers the diverse physiological benefits. We also explored the particular probiotic formulations like VSL#3, Prohep, Lactobacillus rhamnosus GG (LGG), etc., for their ability to modulate immune responses and reduce tumor burden in preclinical models. Targeting the gut microbiome through antibiotics, bacteriophage, microbiome transplantation-based therapies will offer a new perspective in cancer research. Hence, to understand this interplay, we outline the importance of micronutrients with an emphasis on the immunomodulatory function of the microbiome and highlight the microbiome’s potential as a target for precision medicine in cancer treatment.


  • Open Access

    Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis

    by Divya Murthy, Kuldeep S. Attri, Surendra K. Shukla, Ravi Thakur, Nina V. Chaika, Chunbo He, Dezhen Wang, Kanupriya Jha, Aneesha Dasgupta, Ryan J. King, et al.


  • Investigating the Role of KLF6-SV1 as a Regulator of EMT Progression

    by Kanupriya Jha, Amit Kumar, Kartik Bhatnagar, Sarika Chaudhary

    Post-translational modifications (PTMs) are crucial for all biological processes and offer insights into protein functions, including their activity state, subcellular location, solubility, folding, trafficking, and protein−protein interactions. Amino acids modified by PTMs act as molecular switches, influencing protein function and characteristics, and increasing proteome complexity. Krüppel-like transcription factors (KLFs) are a family of transcription factors that regulate essential cellular processes such as proliferation, differentiation, migration, programmed cell death, and various cancer-relevant pathways. In this study we investigated the effect of phosphorylation on the binding affinity and stability of KLF6-SV1 (Krüppel-like factor 6 splice variant 1) interactions with its binding partners, potentially revealing a mechanism for its oncogenic activity. KLF6-SV1 and binding partners interactions were computationally analyzed to evaluate the role of phosphorylation in KLF6-SV1 on their binding affinity and stability. In the present study, it was found that despite a decrease in the binding force between KLF6-SV1 and TWIST1, KLF6-SV1 and MMP9, KLF6-SV1 and SNAI1 upon phosphorylation, the overall energy of each complex decreased, resulting in increased stability. This suggests that phosphorylation plays a significant role in activating KLF6-SV1 and its partner’s oncogenic activities by making the complex stable. This study provides valuable insights into the underlying molecular mechanism of cancer pathogenesis and suggests that KLF6-SV1 phosphorylation is one of the critical events in cancer pathogenesis.

  • Top Cited Papers
    Open Access

    Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis

    by Divya Murthy, Kuldeep S. Attri, Surendra K. Shukla, Ravi Thakur, Nina V. Chaika, Chunbo He, Dezhen Wang, Kanupriya Jha, Aneesha Dasgupta, Ryan J. King, et al.

    The ability of tumour cells to thrive in harsh microenvironments depends on the utilization of nutrients available in the milieu. Here we show that pancreatic cancer-associated fibroblasts (CAFs) regulate tumour cell metabolism through the secretion of acetate, which can be blocked by silencing ATP citrate lyase (ACLY) in CAFs. We further show that acetyl-CoA synthetase short-chain family member 2 (ACSS2) channels the exogenous acetate to regulate the dynamic cancer epigenome and transcriptome, thereby facilitating cancer cell survival in an acidic microenvironment. Comparative H3K27ac ChIP–seq and RNA–seq analyses revealed alterations in polyamine homeostasis through regulation of SAT1 gene expression and enrichment of the SP1-responsive signature. We identified acetate/ACSS2-mediated acetylation of SP1 at the lysine 19 residue that increased SP1 protein stability and transcriptional activity. Genetic or pharmacologic inhibition of the ACSS2–SP1–SAT1 axis diminished the tumour burden in mouse models. These results reveal that the metabolic flexibility imparted by the stroma-derived acetate enabled cancer cell survival under acidosis via the ACSS2–SP1–SAT1 axis.


  • Modulation of Krüppel-like factors (KLFs) interaction with their binding partners in cancers through acetylation and phosphorylation

    by Kanupriya Jha, Amit Kumar, Kartik Bhatnagar, Anupam Patra, Neel Sarovar Bhavesh, Bipin Singh, Sarika Chaudhary


  • Biosensor Assays Types and Their Roles Toward Ligand–Receptor Interactions in Drug Discovery

    by Garima Gupta, Kanupriya Jha, Sarika Chaudhary

    Ligand–receptor interactions (LRIs) are the basis for all the biological processes taking place in living cells and have been exploited to develop and implement in medical field a number of highly sensitive biosensors for the detection of various biomarkers in complex biological fluids. Drug–target interactions, one of the LRIs, are important to understand the biological processes that further help in developing new and better therapeutic molecules. Biosensors based on these interactions give us an idea for the need of modification of existing drugs or to develop new drugs. Common approach to develop biosensors requires the labeling; however, label-free systems provide advantages in avoiding the chances of conformational changes, off-site labeling, and labeling-based hindrances, thus saving time and effort toward assay development. Preliminary drug screening assays are carried out in two-dimensional (2D) models, followed by animal models, which require huge capital investment to reach from bench-top to clinical trials, where only 21% of new compounds make way to phase-1 clinical trials. Three-dimensional culture or organoid culture or organ-on-chip technology has made way for predictive and complex in vitro approach that recapitulates human physiology and represents more similar in vivo behavior than 2D. Multiplexing and nanotechnology have remarkably enhanced the efficacy of biosensors and might lead to a generation of miniaturized biosensors and more than just point-of-care kits. This review provides in-depth analysis of different types of biosensor assays based on drug–target interactions, their advantages, and limitations based on cost, sensitivity, and selectivity and industrial applications.